Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This is a combination of three distinct agents, each with its own mechanism and indication. Mycophenolate mofetil is an immunosuppressant used to prevent organ transplant rejection by inhibiting inosine monophosphate dehydrogenase (IMPDH), thereby blocking lymphocyte proliferation. Phosphodiesterase 5 (PDE5) inhibitors are a class of drugs that increase blood flow by inhibiting the breakdown of cyclic guanosine monophosphate (cGMP), commonly used for erectile dysfunction and pulmonary arterial hypertension. Carnitine is a naturally occurring compound involved in fatty acid metabolism, often supplemented to treat or prevent deficiency, especially in patients with kidney disease on dialysis.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on mycophenolate mofetil + phosphodiesterase 5 inhibitors + carnitine.